非布司他是一种新型选择性黄嘌呤氧化酶抑制剂,主要用于具有痛风症状的高尿酸血症患者的治疗。非布司他的推荐起始剂量为40 mg,1次/d。目前尚无充分依据证实非布司他降尿酸的临床疗效优于别嘌醇,但有研究提示在合并糖尿病或年龄≥65岁的痛风患者中,非布司他80 mg/d组的治疗效果更佳。非布司他常见的不良反应包括肝功能异常、腹泻、头痛、恶心及皮疹等,心血管系统不良反应与别嘌醇比较尚未发现差异有统计学意义。 Febu Butat is a novel and selective xanthine oxidase inhibitor that is mainly used in the treatment of patients with hyperuricemia with gout symptoms. The initial starting dose of febuxostat is 40 mg once daily. There is no sufficient evidence to prove that febuxostat is superior to allopurinol in lowering uric acid clinical efficacy, but studies suggest that in patients with gout or diabetes ≥65 years of age, febuxostat 80 mg / d group Better. Common adverse reactions of febuxostat include liver dysfunction, diarrhea, headache, nausea and skin rashes, cardiovascular adverse reactions and allopurinol no significant difference was found statistically significant.